BIOPHTA
French tech company | Builders Republic
About
Biotech company developing self-administered mucoadhesive ophthalmic inserts — dry tablets built on a patented thiomer biopolymer platform that turn into gel on the eye and release the drug continuously, to replace daily eye drops and intraocular injections in glaucoma and macular oedema.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2020
- City
- RENNES
- Region
- Bretagne
- Tracked rounds
- 1
- Amount raised
- 6.5 M€
Operations
- Seed · 2024
Investors
- Elaia Partners
- GO Capital
- HTL Biotechnology
- Merieux Partners
- UI Investissement
- Unither Pharmaceuticals